<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943590</url>
  </required_header>
  <id_info>
    <org_study_id>16-440</org_study_id>
    <nct_id>NCT02943590</nct_id>
  </id_info>
  <brief_title>STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)</brief_title>
  <official_title>STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will test whether atorvastatin, a drug commonly prescribed for reducing&#xD;
      cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin&#xD;
      is from a family of medications that are commonly called &quot;statins&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the&#xD;
      effectiveness of a drug and determine whether the investigational drug works in treating a&#xD;
      specific disease. &quot;Investigational&quot; means that the drug is being studied.&#xD;
&#xD;
      The chemotherapy drug that the participant have been scheduled to be treated with,&#xD;
      Doxorubicin, has been associated with the development of heart failure in some patients.&#xD;
&#xD;
      This research study is testing whether Atorvastatin can protect the hearts of patients being&#xD;
      treated with Doxorubicin and can reduce cardiac injury and the risk of heart failure.&#xD;
      Atorvastatin is not approved by the FDA (the U.S. Food and Drug Administration) for use to&#xD;
      reduce the cardiac injury after Doxorubicin. Atorvastatin is approved by the FDA for lowering&#xD;
      cholesterol and for reducing the risk of heart attack and stroke. The heart is a muscle that&#xD;
      pumps blood and Atorvastatin may protect the heart by preserving cardiac muscle function.&#xD;
&#xD;
      The investigators will test whether atorvastatin protects the heart using a combination of&#xD;
      imaging tests on the participants heart, blood tests, and stress testing. The imaging tests&#xD;
      will involve an echocardiogram (an echo) and cardiac magnetic resonance (CMR), a type of&#xD;
      magnetic resonance imaging (MRI) scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">October 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine if statins preserve the LVEF at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Events</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether statins reduce cardiac events (new onset heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>To determine The Effect Of Statins On Myocardial Fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T and Global Longitudinal Strain</measure>
    <time_frame>3 months</time_frame>
    <description>To determine whether changes in troponin T or global longitudinal strain by echocardiography at 3 months predict the reduction in LVEF at 12 months on MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A pill taken once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>A pill taken once a day</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  All patients with newly diagnosed NHL and HL&#xD;
&#xD;
          -  Scheduled to receive anthracycline-based therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Statin use or Statin use is indicated based on guidelines&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Unexplained persistent elevation of transaminases (&gt;3 times upper limits of normal)&#xD;
&#xD;
          -  Concomitant use of cyclosporine&#xD;
&#xD;
          -  Renal failure: estimated glomerular filtration &lt;45 mL/min/1.73 m2&#xD;
&#xD;
          -  Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular&#xD;
             clip&#xD;
&#xD;
          -  LVEF of &lt;50% at baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas G Neilan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts general Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tomas G. Neilan, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cancer Treatment Related to Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

